Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.31 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22623220 | 0.98 | EPHX1 (0.34) | EPHX1KDM4AKDM4CADRA1APLA2G2A | |
| SCHEMBL22508903 | 0.88 | EPHX1 (0.44) | EPHX1KDM4AKDM4CADRA1A | |
| SCHEMBL21153756 | 0.84 | ADRA1A (0.32) | ADRA1A | |
| SCHEMBL22295960 | 0.79 | EPHX1 (0.52) | EPHX1PLA2G2A | |
| SCHEMBL20979271 | 0.79 | EPHX2 (0.34) | EPHX1KDM4AKDM4C | |
| SCHEMBL26479933 | 0.79 | PRMT1 (0.33) | ADRA1APLA2G2APRMT1 | |
| SCHEMBL25921070 | 0.79 | EPHX1 (0.44) | EPHX1KDM4AKDM4CADRA1APLA2G2A | |
| SCHEMBL24421542 | 0.77 | ADRA1A (0.31) | ADRA1A | |
| SCHEMBL22218934 | 0.76 | ALDH1A1 (0.41) | EPHX1 | |
| SCHEMBL25725861 | 0.76 | ADRA1A (0.30) | ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4223318-A1 | ANTITUMOR COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Duality Biologics (Suzhou) Co., Ltd. (CN) | 2023-08-09 | — | — | EP | disclosed |